Repaglinid Stada
Repaglinid Stada is a medicine that helps your pancreas make more insulin to lower your blood sugar.
Form
tabletti
Strength
0.5 mg
Active Ingredient
Repaglinide
Manufacturer
STADA Arzneimittel AG
How to Use
Dosage
Your doctor will tell you how much to take. The usual starting dose is 0.5 mg before each main meal.
Method
Take the tablets with a glass of water right before or up to 30 minutes before each main meal.
Important
The maximum dose you can take in a day is 16 mg. Your doctor can adjust your dose up to 4 mg before each main meal.
Possible Side Effects
COMMON
- •Low blood sugar (hypoglycemia)
- •Stomach pain
- •Diarrhea
- •Nausea (feeling sick)
RARE
- •Heart problems (e.g., sudden chest pain)
- •Severe allergic reactions (like swelling of face, trouble breathing, dizziness – seek medical help right away)
- •Vomiting
- •Constipation
- •Vision problems (blurry vision)
- •Severe liver problems (abnormal liver function, increased liver enzymes)
- •Very low blood sugar and loss of consciousness (hypoglycemic coma) – seek medical help right away
- •Skin sensitivity (such as rash, itching, red patches, and swelling)
Important Warnings
- Do not use if you are allergic to repaglinide or any other ingredients in this medicine.
- Do not use if you have type 1 diabetes.
- Do not use if you have high acid levels in your body (diabetic ketoacidosis).
- Do not use if you have severe liver disease.
- Do not use if you are taking a medicine called gemfibrozil (for high fat levels in the blood).
Show 3 more warnings
- Tell your doctor if you have kidney problems, as Repaglinid Stada should be used carefully.
- Tell your doctor if you are having major surgery or have recently had a serious illness or infection.
- Tell your doctor if you are under 18 or over 75 years old, as Repaglinid Stada is usually not recommended for these age groups.
Use in Elderly Patients
Category D
Avoid use in older adults. Risk of hypoglycaemia. Reduce the dose in severe renal impairment. Consider the numerous potential interactions. (updated 10.6.2024)